PFO
MCRB icon

Pathstone Family Office’s Seres Therapeutics MCRB Stock Holding History

Pathstone Family Office’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-395
Closed -$194K – 1057
2020
Q4 		$194K Buy
+395
New +$231K 0.01% 262

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pathstone Family Office's MCRB Position: Q1 2021 in Review

Pathstone Family Office sold out of Seres Therapeutics (MCRB) in Q1 2021, closing a stake of 395 shares — an estimated $194K sold.

Pathstone Family Office first reported a position in MCRB in Q4 2020 and held it in 1 quarter. The position peaked at $194K in Q4 2020. 152 funds tracked by Wall St. Rank hold MCRB as of Q1 2021.

  • Pathstone Family Office reported no remaining Seres Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Pathstone Family Office sold 395 Seres Therapeutics shares in Q1 2021, an estimated $194K.
  • Pathstone Family Office first reported a position in Seres Therapeutics in Q4 2020 and held it in 1 quarter.
  • Pathstone Family Office's Seres Therapeutics position peaked at $194K in Q4 2020.
  • 152 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2021.

Based on Pathstone Family Office's 13F filing for Q1 2021, filed 14 May 2021.